| 摘要: |
| 化学药品上市后变更是药品全生命周期的重要部分。药学变更对调释制剂的安全、有效和质量可控性产生影响的可能性更大。一些口服调释制剂在变更批量、变更注册标准、变更贮藏条件和增加规格时,研究者需按重大变更申报补充申请。本文结合部分化学口服调释制剂上市后变更具体情形,简要论述变更风险评估和变更研究中的药学考虑,期望为变更研究评估和管理提供启示参考。 |
| 关键词: 上市后变更 口服调释制剂 补充申请 变更研究 |
| DOI:10.13506/j.cnki.jpr.2026.02.011 |
| 基金项目: |
|
Publication Date:February 25, 2026
|
|
| Discussion on the research of supplemental applications for post-approval oral modified-release formulations |
| SI Xiaofei,WANG Shuhua,LI Yanjie,JIANG Dianzhuo |
| (Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China) |
| Abstract: |
| The post-approval CMC(chemical, manufacturing and control)changes are important parts of pharmaceutical product lifecycle. The changes considered to have a substantial potential to have a significant effect on safety, efficacy and quality of modified-release formulations. The pharmaceutical sponsors who intend to change the batch size,specification,storage condition and strength of some oral modified-release formulations should submit supplemental applications for major changes. Based on specific cases of oral modified-release formulations, the pharmaceutical considerations were put forward to assess the effects of the change and change research, in order to provide references for conduct change research and management. |
| Key words: Post-approval change Oral modified-release formulations Supplemental applications Change research |